 |
|
Making Progress for How Medicines Are Used in Children
Perdita Taylor-Zapata, MD;
Donald R. Mattison, MD
Arch Pediatr Adolesc Med. 2007;161(9):916.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
We are writing in response to the article "Off-label Drug Use in Hospitalized Children" by Shah et al,1 which describes the magnitude of off-label pediatric prescribing in the United States. We would like to applaud the efforts of the authors in tackling such an important topic, as off-label prescribing potentially puts our children at risk of lack of efficacy due to improper dosing as well as unexpected adverse events. We would, however, like to correct statements made by the authors regarding the role of the National Institutes of Health, specifically the National Institute of Child Health and Human Development (NICHD), in the implementation of the Best Pharmaceuticals for Children Act (BPCA). The authors incorrectly state that they "identified specific drugs that were commonly used off-label that did not appear on the FDA [Food and Drug Administration] list of medications requiring further study in . . . [Full Text of this Article]AUTHOR INFORMATION
RELATED LETTER
Making Progress for How Medicines Are Used in Children—Reply
Samir S. Shah, Matthew Hall, and Anthony D. Slonim
Arch Pediatr Adolesc Med. 2007;161(9):916-917.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Off-label Drug Use in Hospitalized Children
Samir S. Shah, Matthew Hall, Denise M. Goodman, Pamela Feuer, Vidya Sharma, Crayton Fargason, Jr, Daniel Hyman, Kathy Jenkins, Marjorie L. White, Fiona H. Levy, James E. Levin, David Bertoch, and Anthony D. Slonim
Arch Pediatr Adolesc Med. 2007;161(3):282-290.
ABSTRACT
| FULL TEXT
|
